Yuhan Corporation (100.KO)

Overall impact
B (76)

Commentary

Yuhan Corporation is a strong overall performer. With a 'B' rating of 76.3 for overall impact (91st percentile compared to all companies), Yuhan Corporation ranks 3rd out of 22 industry peers, behind Aspira Women’s Health and Biomerieux, and ahead of Amag Pharmaceuticals, Fluoropharma Medical, Trinity Biotech and 16 others. On top material causes for Yuhan Corporation's industry (Pharmaceuticals & Biotech), Yuhan Corporation performs well in Technology Innovation (95.3 score), Access to Affordable Healthcare (96.0), Disease Eradication (96.8) and 1 other cause where it received an 'A' score and performs poorly in Reduced Waste (36.6 score) and Child and Maternal Health (39.7).
Impact
Cause 100.KO
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1926
Employees
2,087
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
South Korea
Share classes
100.KO
Description
Yuhan Corporation manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally. It also manufactures and sells animal feed and health functional food. The company was founded in 1926 and is headquartered in Seoul, South Korea.
Material causes
Ethos considers the following causes material for Yuhan Corporation, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.